logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table INF-18. Trends in HIV prevalence among injecting drug users estimated from national and sub-national samples, 2001 to 2006, samples with average prevalence above 5 %

Germany DT4.63.945.3
Belgium SR13.404.612.9
Sweden SP15.56.4
Belgium SR25.28.14.7
Belgium DT35.
Poland DT6.
Austria DT5.
Latvia DT13.713.16.6
France SR113.713.713.7
Italy DT14.814.814.213.913.812.1
Germany SR1131712
Portugal DT1920.220.2
Spain DT13736.234.531.936.1


 Countries where the average of trend of available data are above 5 %.                

 Seroprevalence studies (SP); diagnostic testing (DT); unlinked anonymous testing (UAT); self-reported tests (SR).               

 Differences between countries have to be interpreted with caution owing to different types of settings and/or study methods; national sampling strategies vary. 

 Data for Italy include non-IDUs and therefore may underestimate prevalence among IDUs.               

 Data for Belgium, Italy and Portugal are limited to prevalence among IDUs in treatment and may not be representative of prevalence among IDUs who are not in treatment. Data for France, and part of the data for Belgium, are based on self-reported test results, which are less reliable than clinically documented tests. 

 1 - Sweden: data from Stockholm; France: data from 12 cities in France; Spain: National data, excluding communities of Madrid and La Rioja; Germany: Frankfurt; Belgium: data from French Community. 

 2 - Belgium: data from Wallon Region.               

 3 - Belgium: data from Antwerp.               

Related links:

 Statistical bulletin 2007: Figure INF-4.               

 See also ‘General notes for interpreting data’ on the Explanatory notes and help page


 Reitox national focal points.               

(see the help page for information about formats etc.)

Page last updated: Wednesday, 16 July 2008